ArticleFrontiers in public health2022

Cost-Effectiveness Analysis of Pembrolizumab in Patients With Advanced Esophageal Cancer Based on the KEYNOTE-181 Study.

Mei Zhan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.